{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.6","upperLimit":"26.3","value":"23.1"},{"groupId":"OG001","lowerLimit":"49.7","upperLimit":"82.8","value":"69.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"description":"Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all participants who were randomly assigned to the DRd or Rd group, and who started subsequent anticancer therapy or died due to progressive disease, whichever occurs first.","reportingStatus":"POSTED","timeFrame":"From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)","title":"Time to Subsequent Anticancer Treatment","type":"SECONDARY","unitOfMeasure":"months"}